Posted: August 31, 2010

Marina Biotech Announces Allowance of Fundamental RNAi Delivery Patent From U.S. Patent Office

(Nanowerk News) Marina Biotech, Inc., a leading RNAi-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application U.S. 11/745,003 broadly covering amphoteric liposomal formulations, including the Company's proprietary SMARTICLESŪ technology, for delivery of siRNAs and other compounds with therapeutic application.
"Delivery of nucleic acids remains the biggest hurdle to successful development of RNAi-based therapeutics," said Barry Polisky, Ph.D., Chief Scientific Officer of Marina Biotech. "Amphoteric liposomes enable the precise control of the charge and fusion properties of a liposome which are key requisites for effective delivery, and do not require additional surface modification to stabilize and mask the particle from undesirable biological interactions. These unique characteristics differentiate amphoteric liposomes from standard liposomes used by others in the RNAi field, and provide a broad platform for the efficient delivery of RNAi-based therapeutics."
"We believe this patent allowance represents the fundamental IP necessary for developing amphoteric liposomal delivery systems for RNAi-based therapeutics," stated J. Michael French, President and CEO at Marina Biotech. "This allowance significantly enhances the company's IP position, and firmly establishes our competitive advantage with respect to RNAi-based delivery systems. In the near future, we expect to see additional patent allowances for Marina Biotech related to our fundamental IP covering the DiLA2 delivery platform, tkRNAi platform (bacterial delivery platform) and our peptide nanoparticle delivery platform."
About Marina Biotech, Inc.
Marina Biotech (formerly known as MDRNA, Inc.) is a biotechnology company, focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Marina's pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech's goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Marina Biotech's global portfolio includes 62 issued or allowed patents; 56 U.S. patent applications; 146 foreign patent applications; and 8 PCT applications providing broad coverage for siRNAs, chemistry, delivery and gene targets. Additional information about Marina Biotech is available at
Source: Marina Biotech (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: